Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma

Dreno, B; Ascierto, PA; Atkinson, V; Liszkay, G; Maio, M; Mandala, M; Demidov, L; Stroyakovskiy, D; Thomas, L; de la Cruz-Merino, L; Dutriaux, C; Garbe, C; Bartley, K; Karagiannis, T; Chang, I; Rooney, I; Koralek, DO; Larkin, J; McArthur, GA; Ribas,

Dreno, B (reprint author), Nantes Univ, Dept Dermato Cancerol, F-44093 Nantes, France.

BRITISH JOURNAL OF CANCER, 2018; 118 (6): 777

Abstract

Background: In the coBRIM study, cobimetinib plus vemurafenib (C+V) significantly improved survival outcomes vs placebo and vemurafenib (P+V) in patie......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索